Lipoprotein(a) and Apolipoprotein(a) in Polycystic Ovary Syndrome.

Objective: Levels of lipoprotein(a), Lp(a), an independent risk factor for cardiovascular disease (CVD), are affected by sex hormones. Women with polycystic ovary syndrome (PCOS) have elevated androgen levels and are at increased CVD risk. We investigated the impact of PCOS-related hormonal imbalance on Lp(a) levels in relation to apo(a) gene size polymorphism, a major regulator of Lp(a) level.

Design: Cross-sectional.

Patients: Forty one Caucasian women with PCOS based on the NIH criteria.

Measurements: 1) Apo(a) gene size polymorphism measured as Kringle (K) 4 repeat number; 2) Total plasma Lp(a) level; 3) Allele-specific apo(a) level assessing the amount of Lp(a) carried by an individual apo(a) allele/isoform; 4) Sex hormone levels.

Results: The mean age was 32±6 years and the mean BMI was 35±8 with 66% of women classified as obese (BMI >30kg/m2 ). LDL cholesterol was borderline high (3.37 mmol/l) and HDL cholesterol was low (1.06 mmol/l). The distribution of Lp(a) level was skewed towards lower levels with a median level of 22.1 nmol/l (IQR: 6.2-66.5 nmol/l). Lp(a) levels were not correlated with age, body weight or BMI. The median allele-specific apo(a) level was 10.6 nmol/l (IQR: 3.1-31.2 nmol/l) and the median apo(a) size was 27 (IQR: 23-30) K4 repeats. Allele-specific apo(a) levels were significantly and inversely correlated with K4 repeats (r=-0.298, p=0.007). Neither Lp(a) or allele-specific apo(a) levels were significantly associated with testosterone or dehydroepiandrosterone sulfate levels.

Conclusions: The apo(a) genetic variability remains the major regulator of plasma Lp(a) levels in women with PCOS.


Read abstract on library site    Access full article